StockData
Polaryx Therapeutics, Inc. logo

Polaryx Therapeutics, Inc. (PLYX) stock

PLYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$1.60−0.07 (-4.19%)

Close on Nov 17, 2026Market cap $79.75MP/E –Yield –

Polaryx Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Polaryx Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $4.41M. For fiscal 2025 it was $6.27M, up 122.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.27M+122.9%
FY2024Dec 31, 2024$2.81M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.45M+376.8%
Q2 FY2026Jun 30, 2026$719.00K+51.1%
Q1 FY2026Mar 31, 2026$679.00K-85.6%
Q4 FY2025Dec 31, 2025$560.00K–
Q3 FY2025Sep 30, 2025$514.00K–
Q2 FY2025Jun 30, 2025$476.00K–
Q1 FY2025Mar 31, 2025$4.72M–

More Polaryx Therapeutics figures

See a number that looks wrong?